Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Chin Liu

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
European Urology|December 21, 2024
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based TherapyVadim S Koshkin, Pongwut Danchaivijitr, Woo Kyun Bae, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.
The Lancet. Diabetes & Endocrinology|July 11, 2024
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M Apperloo, Brendon L Neuen, Robert A Fletcher, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
European Urology|December 21, 2024
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based TherapyVadim S Koshkin, Pongwut Danchaivijitr, Woo Kyun Bae, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.
The Lancet. Diabetes & Endocrinology|July 11, 2024
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M Apperloo, Brendon L Neuen, Robert A Fletcher, et al.
Pageof 5